Press centre

(Earlier today, December 11, 2019, a press release was incorrectly published citing the Market Abuse Regulation (MAR). The information in the press release is regulatory but not of a MAR nature). Jessica Roxhed joins Dicot as CFO, Julie Silber's role...

Jessica Roxhed joins Dicot as CFO, Julie Silber's role as Director of Investor Relations expands and Gabriela Urquilla will head up external communications, reporting to the Director of IR, effective December 15, 2019.

(The previous press release was sent out at 08:00 CET and has been updated to correct a spelling error. Nothing else differs from the previous press release.) November 26, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") The Nominat...

According to the instruction that was adopted at the Dicot AN (Publ) AGM May 16, 2019, the nomination committee should consist of three members.  November 26, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") The Nomination Committee...

November 6, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") announced today that the company has entered into a research collaboration agreement with Pelvipharm, a world-leading contract research organization (CRO) based in France....

Press release: Uppsala, October 4, 2019. Dicot AB (publ, developer of drugs targeting sexual dysfunction, today announced that the company has contracted Catarina Malmberg as its Supply Chain Director, effective of November 1, 2019. In this role Malm...

Dicot AB (publ) ("Dicot" or the "Company") conducted a rights issue of approximately SEK 20.3 million during the period of September 3 - September 17, 2019 (the "Rights Issue"). In connection to the Rights Issue, the Company also conducted a directed...

September 27, 2019, Uppsala, Sweden - The correction relates to addition of information of issuance costs. The press release published on September 20, 2019, does not include such information. The issuance cost of the Right Issue and the Overallotmen...

September 27, 2019, Uppsala, Sweden - The directed issue in Dicot AB (publ) ("Dicot" or the "Company") of 779,082 shares which was made public on September 20, 2019 (the "Overallotment Issue") has been fully subscribed. Through the Overallotment Issu...

The rights issue of units amounting to SEK 20.3 million which was made public on July 23, 2019 (the "Rights Issue") in Dicot AB (publ) ("Dicot" or the "Company") has been heavily oversubscribed. The subscription period ended on September 17, 2019. Th...

September 17, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot") today announced that the company has agreed to sponsor Scandinavian Society for Sexual Medicine (SSSM) and help two upcoming scientists to attend and present their research results at Eu...

September 6, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot") announces that all of its board of directors and parts of management will subscribe for a total of SEK 695 600 in the ongoing rights issue of units (the "Rights Issue").

September 5, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") has appointed Mangold Fondkommission as liquidity provider for the Company"s shares listed on Spotlight Stock Market.

Today on September 3, 2019, the subscription period for the rights issue in Dicot AB (publ) ("Dicot" or the "Company") commences and continues until September 17, 2019. The Company hereby invites shareholders and investors to participate in investmen...

September 2, 2019, Uppsala, Sweden - Dicot AB ("Dicot" or "the Company") has established an investment memorandum related to the Company's rights issue (the "Rights Issue"), which was made public on July 23, 2019. The investment memorandum is now ava...

Press release: Uppsala, August 26, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunctions, today announced that the company has conducted a comparative animal experimental study on the effects of its candidate substance Libiguin® DIC...

An extraordinary general meeting in Dicot AB (publ) was held on 22 August 2019 at Advokatfirman Lindahl's office on Vaksalagatan 10 in Uppsala whereby the shareholders resolved on the following matters.

Press release: Uppsala, August 21, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunction, today announced that Göran Beijer, CEO, will participate and host one-on-one investor meetings at the following upcoming investor conferences: ...

The shareholders in Dicot AB (publ) reg. no. 559006-3490 (the "Company") are hereby convened to the extraordinary general meeting on Thursday, August 22, 2019, at 3 p.m. at Advokatfirman Lindahl's office at Vaksalagatan 10 in Uppsala.